Announcements
(Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Tags: Announcement Source Type: research
GlioVis data portal for visualization and analysis of brain tumor expression datasets
(Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Bowman, R. L., Wang, Q., Carro, A., Verhaak, R. G. W., Squatrito, M. Tags: Letter to the Editor Source Type: research
Targeting tyrosine receptor kinase B in gliomas
(Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Pinheiro, K. V., Alves, C., Buendia, M., Gil, M. S., Thomaz, A., Schwartsmann, G., de Farias, C. B., Roesler, R., Bowman, R. L., Wang, Q., Carro, A., Verhaak, R. G. W., Squatrito, M. Tags: Letter to the Editor Source Type: research
MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis
Conclusions.
PWI-derived thresholds separating viable tumor from treatment changes demonstrate relatively good accuracy in individual studies. However, because of significant variability in optimal reported thresholds and other limitations in the existing body of literature, further investigation and standardization is needed before implementing any particular quantitative PWI strategy across institutions. (Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Patel, P., Baradaran, H., Delgado, D., Askin, G., Christos, P., John Tsiouris, A., Gupta, A. Tags: Clinical Investigation Source Type: research
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas
Conclusion.
Using a machine-learning algorithm, we achieved accurate prediction of IDH genotype in high-grade gliomas with preoperative clinical and MRI features. (Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Zhang, B., Chang, K., Ramkissoon, S., Tanguturi, S., Bi, W. L., Reardon, D. A., Ligon, K. L., Alexander, B. M., Wen, P. Y., Huang, R. Y. Tags: Clinical Investigations Source Type: research
Long-term survival in AIDS-related primary central nervous system lymphoma
Conclusion.
Long-term disease-free survival can be achieved in AR-PCNSL, even among those with histories of opportunistic infections, limited access to health care, and medical non-adherence. Given this, as well as the long-term toxicities of WBRT, we recommend that integration of cART plus first-line HD-MTX be considered for all patients with AR-PCNSL. (Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Gupta, N. K., Nolan, A., Omuro, A., Reid, E. G., Wang, C.-C., Mannis, G., Jaglal, M., Chavez, J. C., Rubinstein, P. G., Griffin, A., Abrams, D. I., Hwang, J., Kaplan, L. D., Luce, J. A., Volberding, P., Treseler, P. A., Rubenstein, J. L. Tags: Clinical Investigations Source Type: research
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials
Conclusions.
Baseline tumor volume is a significant prognostic factor in recurrent GBM. Clinical trial treatment arms must have a balanced distribution of tumor size, and tumor size should be considered when interpreting therapeutic efficacy. (Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Ellingson, B. M., Harris, R. J., Woodworth, D. C., Leu, K., Zaw, O., Mason, W. P., Sahebjam, S., Abrey, L. E., Aftab, D. T., Schwab, G. M., Hessel, C., Lai, A., Nghiemphu, P. L., Pope, W. B., Wen, P. Y., Cloughesy, T. F. Tags: Clinical Investigations Source Type: research
Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome
Conclusions.
PPTIDs can be classified into 1 of 2 novel morphologic subtypes that are associated with distinct clinical outcomes. Tumor grade, neuraxis spread, and extent of resection also influence outcome for patients with PPT. (Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Raleigh, D. R., Solomon, D. A., Lloyd, S. A., Lazar, A., Garcia, M. A., Sneed, P. K., Clarke, J. L., McDermott, M. W., Berger, M. S., Tihan, T., Haas-Kogan, D. A. Tags: Basic and Translational Investigations Source Type: research
CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone
Conclusion.
Together, these data provide evidence on how the adult SVZ environment, through the release of CXCL12, supports GBM therapeutic failure and potential tumor relapse. (Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Goffart, N., Lombard, A., Lallemand, F., Kroonen, J., Nassen, J., Di Valentin, E., Berendsen, S., Dedobbeleer, M., Willems, E., Robe, P., Bours, V., Martin, D., Martinive, P., Maquet, P., Rogister, B. Tags: Basic and Translational Investigations Source Type: research
miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas
Conclusion
This study establishes that miR-423-5p functions as an oncogene in glioma tissues by suppressing ING-4 and suggests that it has therapeutic potential for glioma. (Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Li, S., Zeng, A., Hu, Q., Yan, W., Liu, Y., You, Y. Tags: Basic and Translational Investigations Source Type: research
Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells
Conclusions.
Fatty acid oxidation enzymes are present and active within glioma tissues. Targeting this metabolic pathway reduces energy production and cellular proliferation in glioma cells. The drug etomoxir may provide therapeutic benefit to patients with malignant glioma. In addition, the expression of fatty acid oxidation enzymes may provide prognostic indicators for clinical practice. (Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Lin, H., Patel, S., Affleck, V. S., Wilson, I., Turnbull, D. M., Joshi, A. R., Maxwell, R., Stoll, E. A. Tags: Basic and Translational Investigations Source Type: research
Tyrosine receptor kinase B is a drug target in astrocytomas
Conclusions.
Our findings provide evidence that constitutively activated NTRK2 alleles, notably the human tumor-associated QKI-NTRK2 fusion, can cooperate with Ink4a/Arf loss to drive astrocytoma formation. Therefore, we propose NTRK2 as a potential therapeutic target in the subset of astrocytoma patients defined by QKI-NTRK2 fusion. (Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Ni, J., Xie, S., Ramkissoon, S. H., Luu, V., Sun, Y., Bandopadhayay, P., Beroukhim, R., Roberts, T. M., Stiles, C. D., Segal, R. A., Ligon, K. L., Hahn, W. C., Zhao, J. J. Tags: Basic and Translational Investigations Source Type: research
Highlights from the Literature
(Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Pope, W., Huse, J., Abounader, R., Purow, B., Wick, W., Aldape, K. Tags: Highlights Source Type: research
Where size matters: imaging-based biomarkers for patient stratification
(Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Erickson, B. J., Galanis, E. Tags: Editorial Source Type: research
How bad are your seizures and did the treatment help?
(Source: Neuro-Oncology)
Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Grant, R. Tags: Editorial Source Type: research
